Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 11/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 2/20 | 0.37 |
| ▸ | MC5R | P33032 | 2/20 | 0.37 |
| ▸ | MC3R | P41968 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3593749 | 0.91 | SMYD2 (0.61) | SMYD2L3MBTL1 | |
| SCHEMBL3598104 | 0.90 | SMYD2 (0.53) | SMYD2L3MBTL1 | |
| SCHEMBL3597011 | 0.86 | SMYD2 (0.51) | SMYD2L3MBTL1POLBTACR1MC4R | |
| SCHEMBL2210723 | 0.81 | ADRB2 (0.54) | SMYD2 | |
| SCHEMBL2213786 | 0.81 | ADRB2 (0.54) | SMYD2 | |
| SCHEMBL3584341 | 0.81 | SMYD2 (0.54) | SMYD2 | |
| SCHEMBL3598782 | 0.81 | SMYD2 (0.54) | SMYD2 | |
| SCHEMBL3599007 | 0.81 | SMYD2 (0.62) | SMYD2L3MBTL1 | |
| SCHEMBL13533758 | 0.81 | SMYD2 (0.49) | SMYD2L3MBTL1POLBTACR1MC4R | |
| SCHEMBL2213040 | 0.81 | ADRB2 (0.54) | SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142646-A1 | Novel Compounds 621 | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142646-A1 | Novel Compounds 621 | AR, ADRA1D, ADRA1B | SMYD2 3203/4885L3MBTL1 2855/4885POLB 3878/4885 |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ADRB2, ADRB1, ADRA2A | SMYD2 1024/4885L3MBTL1 2364/4885POLB 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.